Barnes & Noble Shares Soar After Investor Discusses Sale with Founder
07 Sep, 2018
AbbVie Inc. (NYSE: ABBV) reported its fourth quarter financial results for fiscal year 2017. The pharmaceutical company reported better than expected earnings sending shares 13.5 percent before market close on Friday.For the fourth quarter, AbbVie r..
Biogen Inc. (NASDAQ: BIIB) reported its fourth quarter financial results for fiscal year 2017. The U.S. drug-maker fell short on earnings estimates, but topped revenue estimates, sending shares 3 percent higher during Thursday’s pre-marke..
Spark Therapeutics Inc (NASDAQ: ONCE) Luxturna, the first gene therapy in the U.S., has been approved by the Food and Drug Administration. The gene therapy is intended to treat a rare, inherited retinal disease that could possibly cause blindness. U..
Teva Pharmaceutical Industries Ltd (NYSE: TEVA), based in Israel, is one of the world’s largest makers of generic drugs. The pharmaceutical giant has had a rough year, facing declining prices for generic drugs and the loss of a major branded d..
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has announced the cut of 10,000 jobs as the company aims to reduce $1.5 billion to $2 billion in costs over the next two years. Following this announcement, the drug maker’s U.S. shares increase..
While investors were pitched the multiple benefits of the $69 billion CVS Health Corp (NYSE: CVS) - Aetna Inc (NYSE: AET) merger, the former pitched to its shareholders and the general public that this merger could transform the drugstores owned by ..
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its third quarter earnings for fiscal year 2017 and beat analysts’ estimates, sending shares up almost 7 percent shortly after open on Wednesday.For the third quarter, Regeneron reported r..
All rights reserved.
No portion of Financialinsiders.com may be duplicated, redistributed or manipulated in any form without our consent, violators will be prosecuted to the full extent of the law. By accessing any information beyond this page, you agree to abide by the Privacy Policy and Terms of Use (Disclaimer).